Abstract
Pharmacia Corp (formerly GD Searle & Co) is developing eplerenone, an aldosterone receptor antagonist, as a potential treatment for congestive heart failure and systemic hypertension. The compound has been registered for hypertension and Pharmacia plans to submit a supplemental NDA for congestive heart failure in the first half of 2003 based on positive results from a phase III clinical trial.
MeSH terms
-
Animals
-
Clinical Trials as Topic
-
Eplerenone
-
Humans
-
Hypertension / drug therapy
-
Hypertension / metabolism
-
Mineralocorticoid Receptor Antagonists* / adverse effects
-
Mineralocorticoid Receptor Antagonists* / pharmacology
-
Mineralocorticoid Receptor Antagonists* / therapeutic use
-
Spironolactone* / adverse effects
-
Spironolactone* / analogs & derivatives*
-
Spironolactone* / pharmacology
-
Spironolactone* / therapeutic use
Substances
-
Mineralocorticoid Receptor Antagonists
-
Spironolactone
-
Eplerenone